Business programme
21 June
10:00–11:15
Congress Centre in zone E, Healthy Life Area
Innovation in Pharmaceuticals: New Opportunities for the Development of Medical Technologies
The modern pharmaceutical industry is a unique symbiosis of academic science, a wide range of applied disciplines, industry, and regulatory practice. The healthcare industry views people’s well-being as a priority goal and is one of the key factors in the development of medical technologies and innovations to protect their health. New technologies for healthy and active longevity are constantly emerging as a result of scientific progress. Collaboration between science and the pharmaceutical industry makes it possible to scale up and incorporate such technologies into practice, as well as influence the availability of medical and pharmaceutical products to a wide range of patients. The introduction of innovative drugs and the development of new approaches to the treatment of rare and socially significant diseases is a modern reality for the harmonious development of healthcare in Russia. Success in this regard can be achieved through the consolidated efforts of the pharmaceutical industry and the government, the social responsibility of business, effective state support mechanisms for innovation, and a flexible and effective system of legal regulation. What environment and conditions are needed for the development and introduction of advanced medical technologies and pharmaceutical products? How do pharmaceutical innovations affect the comprehensive development of medicine? What opportunities for the development of pharmaceutical innovations will be available in Russia in the near future? What examples of the successful introduction of pharmaceutical innovations already exist?
Valentina Kosenko — Acting General Director, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
Kamila Zarubina — Managing Director of Biological and Medical Technologies, Deputy Chief Managing Director for Priority Technology Areas, Skolkovo Foundation
Kira Zaslavskaya — New Products Director, "Promomed" Group of Companies
Vikram Punia — President, Pharmasyntez Group of Companies
Evgeny Shlyakhto — General Director, Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation; Chief Visiting Cardiologist Specialist of the Ministry of Health of the Russian Federation
Moderator:
Valentina Kosenko — Acting General Director, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
Panellists:
Konstantin Belanov — Director, Center for Transfer of Medical Technologies, Scientific Center for Expertise of Medical Products of the Ministry of Health of the Russian Federation
Dmitry Borisov — General Director, POLYSAN
Kamila Zarubina — Managing Director of Biological and Medical Technologies, Deputy Chief Managing Director for Priority Technology Areas, Skolkovo Foundation
Kira Zaslavskaya — New Products Director, "Promomed" Group of Companies
Kira Zaslavskaya has more than 10 years of experience in the medical sector. She started her career as a medical representative and now she is a top manager at a major pharmaceutical company.
In 2009, she joined the team of Promomed Group. As Director for New Products, she is responsible for the product portfolio development strategy, the introduction of new technologies in the development of medicines, the organization of preclinical and clinical trials and the launch of products on the market.
Kira Zaslavskaya participated in the implementation of the world’s largest observational post-marketing study in endocrinlogy of the efficacy and safety of Reduxin®, as well as in the development, study and market launch of Areplivir®, the drug for coronavirus infection.
She graduated from the Mendeleev Russian University of Chemical Technology and passed postgraduate training program at the Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences. She is an author of numerous scientific papers, a competent speaker at industry events.
In 2009, she joined the team of Promomed Group. As Director for New Products, she is responsible for the product portfolio development strategy, the introduction of new technologies in the development of medicines, the organization of preclinical and clinical trials and the launch of products on the market.
Kira Zaslavskaya participated in the implementation of the world’s largest observational post-marketing study in endocrinlogy of the efficacy and safety of Reduxin®, as well as in the development, study and market launch of Areplivir®, the drug for coronavirus infection.
She graduated from the Mendeleev Russian University of Chemical Technology and passed postgraduate training program at the Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences. She is an author of numerous scientific papers, a competent speaker at industry events.
Sergey Onikienko — President, Alternative Innovative Technologies; Chief Researcher, St. Petersburg Scientific Center of the Russian Academy of Sciences
Vikram Punia — President, Pharmasyntez Group of Companies
Born on March 15, 1973 in Jaipur, India. Russian citizen.
Graduated from Birla High School in Pilani. In 1992 started his higher education in Russia, at Irkutsk State Medical University. Later graduated from the Far Eastern Federal University, majoring in Finance and Credit. Married, with three children.
Founder of Pharmasyntez, member of the Leaders’ Club to Promote Business Initiatives (a non-profit partnership), Co-Chairman of the Business Council for Cooperation with India, participant in several investment forums and business missions.
Pharmasyntez manufactures medicinal drugs for socially significant diseases, such as tuberculosis, HIV/AIDS, cancer, hepatitis and diabetes. The company’s profile includes over 113 various pharmaceutical forms and dosages – caps, pills, granules, IV solutions, sterile dry powders, solutions for injection and lyophilisates. Currently Pharmasyntez has five GMP compliant manufacturing facilities in the following Russian cities: Saint Petersburg, Tyumen, Bratsk, Irkutsk and Ussuriysk. The company employs over 1500 qualified specialists.
Pharmasyntez was number one Russian pharmaceutical manufacturer based on hospital purchases in 2016 (and No. 5 out of all pharmaceutical manufacturers, based on hospital purchases records). In 2016 it also became the fastest growing Russian manufacturing company with the revenue of 12 billion, which has doubled in comparison with 2014.
Currently Pharmasyntez is Russia’s leader in manufacturing medicinal agents for tuberculosis, retrovirus and cancer. Farmasintez does innovative R&D and exports pharmaceutical agents from Russia. The company is Irkutsk’s biggest tax payer.
Graduated from Birla High School in Pilani. In 1992 started his higher education in Russia, at Irkutsk State Medical University. Later graduated from the Far Eastern Federal University, majoring in Finance and Credit. Married, with three children.
Founder of Pharmasyntez, member of the Leaders’ Club to Promote Business Initiatives (a non-profit partnership), Co-Chairman of the Business Council for Cooperation with India, participant in several investment forums and business missions.
Pharmasyntez manufactures medicinal drugs for socially significant diseases, such as tuberculosis, HIV/AIDS, cancer, hepatitis and diabetes. The company’s profile includes over 113 various pharmaceutical forms and dosages – caps, pills, granules, IV solutions, sterile dry powders, solutions for injection and lyophilisates. Currently Pharmasyntez has five GMP compliant manufacturing facilities in the following Russian cities: Saint Petersburg, Tyumen, Bratsk, Irkutsk and Ussuriysk. The company employs over 1500 qualified specialists.
Pharmasyntez was number one Russian pharmaceutical manufacturer based on hospital purchases in 2016 (and No. 5 out of all pharmaceutical manufacturers, based on hospital purchases records). In 2016 it also became the fastest growing Russian manufacturing company with the revenue of 12 billion, which has doubled in comparison with 2014.
Currently Pharmasyntez is Russia’s leader in manufacturing medicinal agents for tuberculosis, retrovirus and cancer. Farmasintez does innovative R&D and exports pharmaceutical agents from Russia. The company is Irkutsk’s biggest tax payer.
Evgeny Shlyakhto — General Director, Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation; Chief Visiting Cardiologist Specialist of the Ministry of Health of the Russian Federation
Professor Evgeny Shlyakhto, Director General of the Almazov National Medical Research Centre, Academician of the Russian Academy of Science, President of the Russian Society of Cardiology, Fellow of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology.
Professor Shlyakhto was born on June 29, 1954 in Pogar, the Bryansk region. He graduated from the Pavlov Medical University in Saint Petersburg in 1977 and became Doctor of Science in Medicine in 1992, Professor in 1994, Honored Russian Scientist in 2004, and Academician of the Russian Academy of Sciences in 2014.
Evgeny Shlyakhto has been the Director General of the Almazov National Medical Research Centre since 2001 and the President of the Russian Society of Cardiology since 2011. In 2010, he became a member of the WHO Expert Working Group.
The Centre led by Prof. Shlyakhto carries out intensive research in the fields of translational medicine, molecular diagnostics, development of diagnostic tools for personalized treatment, cellular and tissue engineering for therapeutic purposes, creation of biocompatible materials and tissue-engineered constructs designed to create breakthrough medical technologies of fundamental importance for providing high-tech care to patients with cardiovascular, endocrine and blood diseases.
The results of research work by Prof. Shlyakhto have been summarized in more than 800 publications, 16 inventions, 2 scientific discoveries, and a number of monographs. Prof. Shlyakhto was a supervisor in 57 PhD and 20 DSc students..
Professor Shlyakhto is a member of the Presidium of the Russian Academy of Science, the Presidential Council for Science and Education, the Regional Health Council under the Federation Council of the Russian Federal Assembly, the Expert Health Council of the Federation Council Committee on Social Policy of the Russian Federal Assembly, Vice President of the National Medical Chamber.
Evgeny Shlyakhto is the Editor-in-Chief of the following medical journals: Russian Journal of Cardiology, Translational Medicine, and Journal of Arrhythmology. He also is a member of the international editorial board of the European Heart Journal.
Professor Shlyakhto plays an active role in such international committees as the ESC Congress Programme Committee (since 2012) and of the ESC Committee for Practice Guidelines (since 2015).
Evgeny Shlyakhto received the Russian Federation Government Prize in science and technology in 2009 and won the Pavlov Award, the prize for scientific and technological achievement in Physiology and Medicine from the Saint Petersburg Government and St. Petersburg Scientific Center of the Russian Academy of Sciences, in 2011. He received an Order of Honour in 2012 and 4th class Order of Merit for the Motherland in 2017.
Professor Shlyakhto was born on June 29, 1954 in Pogar, the Bryansk region. He graduated from the Pavlov Medical University in Saint Petersburg in 1977 and became Doctor of Science in Medicine in 1992, Professor in 1994, Honored Russian Scientist in 2004, and Academician of the Russian Academy of Sciences in 2014.
Evgeny Shlyakhto has been the Director General of the Almazov National Medical Research Centre since 2001 and the President of the Russian Society of Cardiology since 2011. In 2010, he became a member of the WHO Expert Working Group.
The Centre led by Prof. Shlyakhto carries out intensive research in the fields of translational medicine, molecular diagnostics, development of diagnostic tools for personalized treatment, cellular and tissue engineering for therapeutic purposes, creation of biocompatible materials and tissue-engineered constructs designed to create breakthrough medical technologies of fundamental importance for providing high-tech care to patients with cardiovascular, endocrine and blood diseases.
The results of research work by Prof. Shlyakhto have been summarized in more than 800 publications, 16 inventions, 2 scientific discoveries, and a number of monographs. Prof. Shlyakhto was a supervisor in 57 PhD and 20 DSc students..
Professor Shlyakhto is a member of the Presidium of the Russian Academy of Science, the Presidential Council for Science and Education, the Regional Health Council under the Federation Council of the Russian Federal Assembly, the Expert Health Council of the Federation Council Committee on Social Policy of the Russian Federal Assembly, Vice President of the National Medical Chamber.
Evgeny Shlyakhto is the Editor-in-Chief of the following medical journals: Russian Journal of Cardiology, Translational Medicine, and Journal of Arrhythmology. He also is a member of the international editorial board of the European Heart Journal.
Professor Shlyakhto plays an active role in such international committees as the ESC Congress Programme Committee (since 2012) and of the ESC Committee for Practice Guidelines (since 2015).
Evgeny Shlyakhto received the Russian Federation Government Prize in science and technology in 2009 and won the Pavlov Award, the prize for scientific and technological achievement in Physiology and Medicine from the Saint Petersburg Government and St. Petersburg Scientific Center of the Russian Academy of Sciences, in 2011. He received an Order of Honour in 2012 and 4th class Order of Merit for the Motherland in 2017.
21 June
11:45–13:00
Congress Centre in zone E, Healthy Life Area
Health with a Woman’s Face: The Power of Communities in the Social Sector
Women are conduits of health values. However, their role is not only to take responsibility for shaping healthy habits in families and society; they are one of the main pillars of the state policy for social change. Women find their purpose in improving people’s health and living standards, as well as building a healthy environment for them, and they direct their power precisely where the state needs the greatest support with resources. Thanks to the integrated efforts of women’s social initiatives, various agencies, and the government, the social sector is turning into a holistic ecosystem, where a seamless model of social and medical care is taking shape. The unification into communities of all women who are implementing their own social initiatives and projects makes each of them part of a single driving force in achieving the national goal of increasing the duration and quality of people’s lives. What specific areas of socially oriented assistance need public projects and initiatives the most today? How do local projects help to increase people’s overall satisfaction with social and medical care? What successful initiatives to shape healthy habits and a health-conscious environment in society in terms of nutrition, active lifestyle, and preventing risk factors are becoming a source of support for the government’s health preservation programmes? How can we build an effective model of interaction between the government and non-commercial organizations and promote the replication of best social practices in the country’s regions? What is the best way to unite women leaders and innovators of the social agenda and scale up the activities of women’s communities in the interests of a healthy society?
Olga Starikova — General Director, Mosprom
Natalya Bondarenko — Chief Physician, Clinical Hospital No. 85 of the Federal Medical and Biological Agency
Elena Koblyuk — Vice President of Human Resources, Health&Nutrition
Natalia Darbinyan — Head of the Department of Congress and Exhibition Activities and Protocol, Center for Support of Export, Industry and Investment Activities; member of the public council under the Ministry of Health of the Russian Federation
Saniyam Koval — President, Charity Foundation Give Sunlight
Yulia Lapshina — Founder, Communications Agency Brand Navigator Agency
Olga Postnikova — Chief Executive Officer, Dobroe Delo Social Care Centre
Moderator:
Olga Starikova — General Director, Mosprom
Panellists:
Christina Bondareva — Chief physician, Vetkovskaya Central Regional Hospital
Natalya Bondarenko — Chief Physician, Clinical Hospital No. 85 of the Federal Medical and Biological Agency
Elena Koblyuk — Vice President of Human Resources, Health&Nutrition
Elena Semeleva — Deputy Head of the Administration of the Head of the Republic of Mordovia and the Government of the Republic of Mordovia
— CEO, The Star Port Foundation
Front row participants:
Alyona Gerasimovich — Founder of the gluten-free cafe and pastry shop "Without a recipe", author of 3 cookbooks, popularizer of a mild healthy lifestyle
Natalia Darbinyan — Head of the Department of Congress and Exhibition Activities and Protocol, Center for Support of Export, Industry and Investment Activities; member of the public council under the Ministry of Health of the Russian Federation
Saniyam Koval — President, Charity Foundation Give Sunlight
Yulia Lapshina — Founder, Communications Agency Brand Navigator Agency
Olga Postnikova — Chief Executive Officer, Dobroe Delo Social Care Centre
21 June
13:30–14:45
Congress Centre in zone E, Healthy Life Area
Cost-Effective Health Preservation: Modern Opportunities
Preserving and increasing the size of the population is one of Russia’s top national priorities. In the current demographic situation, it is imperative to enhance the efficiency of the healthcare system by altering the existing paradigm: instead of a curative healthcare model, a preventive approach should be introduced. Whereas the former involves a model of disease-centred medical care in which healthcare turns into a system of expensive medical services for limited segments of the population, the doctor is a seller, and the patient is a customer, in the latter case, the efforts of the healthcare system are primarily aimed at introducing the concept of a healthy lifestyle, eliminating risk factors, ensuring the early detection and timely treatment of diseases, and preventing complications. The principle of ‘medicina preventive’ is consistent with the model of Nikolay Semashko, in which the main value is not market interests, but the actual person. In recent decades, there has been explosive growth in preventive medicine with a huge focus on public health, i.e. the primary healthcare link, and impressive results have been achieved despite minimal resources. Integrating the methodological foundations of ‘Semashko’s medicine’ and modern prevention technologies is the key to preserving the health of the Russian people. What opportunities are being created by the practical introduction of preventive technologies at the individual and social levels? What preventive medicine technologies could significantly improve people’s quality and duration of life? What is the best way to integrate the concept of ‘Semashko’s medicine’ and modern prevention technologies as elements of an integrated healthcare system? What benefits can the medical business bring to public health?
Oleg Apolikhin — Member, Public Chamber of the Russian Federation; Chief Male Reproductive Health Specialist of the Ministry of Health of the Russian Federation; Honoured Doctor of the Russian Federation
Maria Grudina — Сo-Founder, "First Line. Health Care Resort"
Alla Ivanova — Head of Demography Department, Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
Alexander Razumov — President, National Resort Association; Academician, Russian Academy of Sciences
Elena Chichkanova — Managing Partner, Director of Communications, MAYRVEDA
Moderator:
Oleg Apolikhin — Member, Public Chamber of the Russian Federation; Chief Male Reproductive Health Specialist of the Ministry of Health of the Russian Federation; Honoured Doctor of the Russian Federation
Apolikhin O.I. is a graduate of Voronezh State Medical Institute and has received his MD from the Scientific Research Institute of urology of the Health Ministry of Russia. He extended his education with several abroad trainings: Medical Technical University (ACTIM) France, Medical and Economic faculty, course in health care economics and new technologies and modern equipment utilization. Oxford University (England), MBA faculty, course in medical ethics and administrative law in health care. Oxford University (England), course in evidence based medicine. Professor Apolikhin is actively involved in state health care structure being chief specialist in Reproductive Health of the Ministry of Health Care of Russia. He systematically holds scientific, organizational and methodical activity in reproductive health in Russian regions. Professor Apolikhin has been recognized nationally and internationally through his international memberships which include European Urological Association, American Urological Association and Royal Society of Medicine (UK). He studied Administrative ethical issues in health care at Oxford University, where he also received MSc in evidence-based health care. Professor Apolikhin holds editorial positions on several well-respected journals, including Russian Journal of Urology. He has authored and co-authored more than 500 articles, edited and co-edited 10 books, has multiple multimedia presentations to his credit. His extensive experience in the field of urology and andrology has afforded him the opportunity to participate in academic activities, meetings and courses as a speaker and chairperson. Fields of his interest are postgraduate medical education upgrading, modernization of Russian health care system, men’s health evaluation and management.
Panellists:
Evgeniya Gorbunova — First Deputy Director General, JSC Medscan
Maria Grudina — Сo-Founder, "First Line. Health Care Resort"
Alla Ivanova — Head of Demography Department, Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
Doctor of Economic Sciences, Professor.
Head of the Department of Health and Self-Preservation Behavior, Institute of Demographic Research, Federal Research Sociological
center of the Russian Academy of Sciences
Head of the Department of Health and Self-Preservation Behavior, Institute of Demographic Research, Federal Research Sociological
center of the Russian Academy of Sciences
Alexander Razumov — President, National Resort Association; Academician, Russian Academy of Sciences
President of State-Owned Autonomous Medical Facility Moscow Research and Practical Centre for Medical Rehabilitation and Reconstructive and Sports Medicine of the Moscow Department of Healthcare, full member of the Russian Academy of Sciences, Doctor of Medicine Alexander Rasumov was born in 1944 in Sheperovo, Chaussky District, Mogilev Region. From 1960 to 1970, he studied at the Chernigov Higher School for Air Force Pilots and Engineers and the Grodno Institute of Medicine and the Saratov Institute of Medicine. From 1970 to 1990, he worked at the Defence Ministry’s Institute of Aviation and Space Medicine. From 1990 to 1992: Director, Research and Production Centre Rabotosposobnost of the USSR Ministry of Oil and Gas Construction. From 1992 to 1998: CEO, Moscow Centre for Health Problems under the Government of Moscow. From 1998 to 2010: Director, Federal State-Owned Institution Russian Research Centre for Rehabilitative Medicine and Resorts of the Ministry of Healthcare. Holds the title of Distinguished Scientist of the Russian Federation, laureate of the Prize of the Government of the Russian Federation, President of the International University of Rehabilitative Medicine, of the National Resort Association and of the Russian Society of Rehabilitative Medical Doctors, member of the Board of the National Medical Chamber, member of the Russian-German Council, Professor Emeritus of Liverpool University, Russian representative in and member of the WHO European Committee for Global Health Policy, Chairman of the FEMTEC Medical Commission. Alexander Rasumov led the drafting and approval of the Concept for State Policy on Resort Development in the Russian Federation. He has been decorated with the Order of Service to Motherland in the Armed Forces 3rd Degree, the Order of Friendship, the Medal for Valiance in Combat, etc. Aleander Rasumovis a laureate of the Profession Life international prize, the Mikhail Lomonosov Prize in the field of Science and Education and the Russian Ministry of Healthcare and Social Development Russia’s Best Doctor: The Mission prize, recipient of a diploma of the N.A. Semashko Russian Academy of Medical Sciences prize for the best paper on the theory and history of healthcare.
Elena Chichkanova — Managing Partner, Director of Communications, MAYRVEDA
Front row participants:
Natalya Kostina — Deputy General Director, JSC "St. Petersburg Agency for Medical Tourism"; Committee Member, Committee for Tourism Development of St. Petersburg
Varavara Paal — Director of Public Relations, NaftaGaz JSC